Insight

Oct 29, 2024, 17:17

Myeloma Paper of the Day, October 29th, suggested by Robert Orlowski

“Myeloma Paper of the Day: A Markov model from the health care system perspective for patients with MGUS suggests LDCT and WBMRI + DIFF can be the most cost-effective imaging strategies for the initial diagnosis of progression to myeloma.”

“Multiple myeloma: What is the most cost-effective imaging strategy for initial detection of bone lesions?”

Authors: Soterios Gyftopoulos, Arnau Hanly, Naveen Subhas, Noopur Raje and Connie Chang.

More posts featuring Robert Orlowski.

Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.

Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response. Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.